

# Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

## Panc 08.13

RRID:CVCL\_1638

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_1638

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1638](https://web.expasy.org/cellosaurus/CVCL_1638)

**Proper Citation:** RRID:CVCL\_1638

**Description:** Cell line Panc 08.13 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Pancreatic ductal adenocarcinoma

**Defining Citation:** [PMID:9612602](#), [PMID:14695172](#), [PMID:16912165](#), [PMID:18000365](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:22753594](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

**Comments:** Population: Caucasian., From: Johns Hopkins University School of Medicine; Baltimore; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** Panc 08.13

**Synonyms:** Panc 8.13, Panc-08.13, PANC-08-13, Panc\_08\_13, Panc08.13, Panc8.13, Panc-8\_13, Panc-813, PANC 813, Panc813, PANC813, PANC0813, Panc0813, Pa14C, PL9, PL-9

**Cross References:** CLO:CLO\_0008379, EFO:EFO\_0006470, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-

3610, ATCC:CRL-2551, BioGRID\_ORCS\_Cell\_line:189, BioSample:SAMN03472947, BioSample:SAMN10988145, cancercellines:CVCL\_1638, Cell\_Model\_Passport:SIDM01136, ChEMBL-Cells:ChEMBL3308777, ChEMBL-Targets:ChEMBL1075558, Cosmic:925347, Cosmic:949526, Cosmic:1198215, Cosmic:1198221, Cosmic:1473126, Cosmic:1509858, Cosmic:2434104, Cosmic-CLP:925347, DepMap:ACH-000417, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:925347, GEO:GSM206531, GEO:GSM621905, GEO:GSM784709, GEO:GSM827278, GEO:GSM887499, GEO:GSM888581, GEO:GSM1024410, GEO:GSM1374813, GEO:GSM1670334, LiGeA:CCLE\_501, LINCS\_LDP:LCL-1742, PharmacnoDB:Panc08\_13\_1244\_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL\_1638, PubChem\_Cell\_line:CVCL\_1638, Wikidata:Q54937528

**ID:** CVCL\_1638

**Record Creation Time:** 20220427T221408+0000

**Record Last Update:** 20260829T235537+0000

---

## Ratings and Alerts

No rating or validation information has been found for Panc 08.13.

No alerts have been found for Panc 08.13.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 9 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Dobersch S, et al. (2025) HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. Nature communications, 16(1), 4866.

Wang S, et al. (2025) IFN- $\gamma$ -driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. Nature communications, 16(1), 10733.

Drizyte-Miller K, et al. (2025) Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. Cancer research, 85(18), 3540.

Cao M, et al. (2025) PPY-Induced iCAFs Cultivate an Immunosuppressive Microenvironment in Pancreatic Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(20), e2413432.

Yuan L, et al. (2025) Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degradator of the Nuclear Pore Complex. *Cancer discovery*, 15(12), 2505.

Yu J, et al. (2024) Ultra-large scale virtual screening identifies a small molecule inhibitor of the Wnt transporter Wntless. *iScience*, 27(8), 110454.

Vogt M, et al. (2024) Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2. *Gut*, 73(9), 1509.

Stalneck CA, et al. (2022) Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. *Cancer research*, 82(4), 586.

Krenz B, et al. (2021) MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. *Cancer research*, 81(16), 4242.